1. Home
  2. A vs ONC Comparison

A vs ONC Comparison

Compare A & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agilent Technologies Inc.

A

Agilent Technologies Inc.

HOLD

Current Price

$138.35

Market Cap

39.8B

Sector

Industrials

ML Signal

HOLD

ONC

BeiGene Ltd. American Depositary Shares

HOLD

Current Price

$311.76

Market Cap

34.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
A
ONC
Founded
1999
2010
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.8B
34.8B
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
A
ONC
Price
$138.35
$311.76
Analyst Decision
Buy
Strong Buy
Analyst Count
15
12
Target Price
$162.80
$369.50
AVG Volume (30 Days)
2.2M
269.5K
Earning Date
11-24-2025
11-06-2025
Dividend Yield
0.74%
N/A
EPS Growth
3.16
N/A
EPS
4.57
0.58
Revenue
$6,948,000,000.00
$4,972,687,000.00
Revenue This Year
$8.00
$895.40
Revenue Next Year
$6.29
$22.04
P/E Ratio
$30.27
$533.14
Revenue Growth
6.73
50.43
52 Week Low
$96.43
$172.67
52 Week High
$160.27
$385.22

Technical Indicators

Market Signals
Indicator
A
ONC
Relative Strength Index (RSI) 39.84 41.88
Support Level $136.23 $306.61
Resistance Level $139.19 $318.12
Average True Range (ATR) 2.54 8.43
MACD -0.63 -0.78
Stochastic Oscillator 15.66 36.90

Price Performance

Historical Comparison
A
ONC

About A Agilent Technologies Inc.

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.

Share on Social Networks: